Publication details
Aktualizace Doporučení ESC pro diagnostiku a léčbu akutního a chronického srdečního selhání 2021. Vypracovaná Pracovní skupinou pro diagnostiku a léčbu akutního a chronického srdečního selhání Evropské kardiologické společnosti (ESC). Se zvláštním přispěním Evropské asociace srdečního selhání ESC.
| Title in English | 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC |
|---|---|
| Authors | |
| Year of publication | 2024 |
| Type | Article in Periodical |
| Magazine / Source | cor et Vasa |
| MU Faculty or unit | |
| Citation | |
| web | https://e-coretvasa.cz/artkey/cor-202402-0006_aktualizace-doporuceni-esc-pro-diagnostiku-a-lecbu-akutniho-a-chronickeho-srdecniho-selhani-2021-vypracovana-p.php |
| Doi | http://dx.doi.org/10.33678/cor.2024.018 |
| Keywords | acute heart failure; chronic kidney disease; comorbidities; diagnosis; ejection fraction; guidelines; heart failure; hospitalization; multidis- ciplinary management; natriuretic peptides; neurohormonal antagonists; pharmacotherapy; prevention |
| Description | Updates to the recommendations are made when they are published new evidence that has the potential to influence clinical practice prior to the release of further complete new recommendations. This document provides new and revised recommendations for the ESC Guidelines for the Diagnosis and Treatment of Acute and chronic heart failure 2021. The members of the working group conducted a critical appraisal of of diagnostic and therapeutic approaches, including an assessment of the balance of benefits and risks. All approved recommendations were subject to a vote, which had to reach 75% consensus among voting members. This update was prepared after careful consideration of the scientific and medical knowledge and evidence available at the time of the document's creation. It may present off-label use of drugs if proven, that they can be considered appropriate for the condition. Final decisions regarding an individual patient, however, must be made by a responsible health professional with specific consideration of: - The specific situation of the patient. If, according to national regulations, the use of off-label use should be limited to situations where it is in the interest of the patient with regard to quality, safety and effectiveness of care, and only after the patient has been informed and has given consent. - Country-specific health regulations, indications from the governmental drug regulatory agency and, where applicable, ethical rules to which health professionals are subject. |